Skip to main
NYXH

Nyxoah SA (NYXH) Stock Forecast & Price Target

Nyxoah SA (NYXH) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 67%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nyxoah is well-positioned for future success due to its strong first quarter performance and positive outlook for future revenue growth. With a successful U.S. commercial launch and increasing sales forces, the company is expected to drive significant revenue growth in the coming years. Additionally, the pending results of the ACCCESS study could provide further opportunities for expansion in 2027. Overall, Nyxoah has the potential to become a high-growth asset in the medical technology market.

Bears say

Nyxoah is facing risks in terms of standard adoption and obtaining additional capital, especially in a market dominated by larger competitors. While 2026 may present some potential for investor confidence with the company's progress in commercialization and personnel updates, the lowered valuation multiple and potential regulatory risks associated with its ACCCESS study are concerning for its long-term potential and profitability. The company's success in the fourth quarter of 2025 may provide a temporary boost, but repeat orders in the first quarter of 2026 will be a key indicator of sustained commercial success.

Nyxoah SA (NYXH) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 67% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nyxoah SA (NYXH) Forecast

Analysts have given Nyxoah SA (NYXH) a Buy based on their latest research and market trends.

According to 3 analysts, Nyxoah SA (NYXH) has a Buy consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nyxoah SA (NYXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.